JP2013523891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523891A5 JP2013523891A5 JP2013505087A JP2013505087A JP2013523891A5 JP 2013523891 A5 JP2013523891 A5 JP 2013523891A5 JP 2013505087 A JP2013505087 A JP 2013505087A JP 2013505087 A JP2013505087 A JP 2013505087A JP 2013523891 A5 JP2013523891 A5 JP 2013523891A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- oxo
- pyrimidinediamine
- pyrido
- oxazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 121
- -1 2-oxa-5-azabicyclo [2.2.1] heptanyl Chemical group 0.000 claims description 108
- 125000003118 aryl group Chemical group 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 80
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- 239000001257 hydrogen Substances 0.000 claims description 55
- 150000002431 hydrogen Chemical class 0.000 claims description 44
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 40
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 25
- 125000004104 aryloxy group Chemical group 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- CJUIETFEBPSWEU-CYBMUJFWSA-N 6-[[5-fluoro-2-[[6-[(3r)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CC[C@@H](O)C1 CJUIETFEBPSWEU-CYBMUJFWSA-N 0.000 claims description 6
- VIBOBCDICAAZKZ-ZDUSSCGKSA-N 6-[[5-fluoro-2-[[6-[(3s)-3-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C[C@H]1COCCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 VIBOBCDICAAZKZ-ZDUSSCGKSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- MMQMXAFTMMKGRN-ZDUSSCGKSA-N 6-[[5-fluoro-2-[[6-[(2s)-2-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@@H](C)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 MMQMXAFTMMKGRN-ZDUSSCGKSA-N 0.000 claims description 5
- RYMXNBYSVABIPZ-CQSZACIVSA-N 6-[[5-fluoro-2-[[6-[(3r)-3-methoxypyrrolidin-1-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@H](OC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 RYMXNBYSVABIPZ-CQSZACIVSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 229910052717 sulfur Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- UNVFYFLPCKFDCE-UHFFFAOYSA-N 1-[5-[[4-[(2,2-dimethyl-3-oxo-4h-pyrido[3,2-b][1,4]oxazin-6-yl)amino]-5-fluoropyrimidin-2-yl]amino]pyridin-2-yl]pyrrolidine-3-carboxamide Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCC(C(N)=O)C1 UNVFYFLPCKFDCE-UHFFFAOYSA-N 0.000 claims description 3
- WPLSNJRTQSTZGY-UHFFFAOYSA-N 6-[[2-[[6-(2,2-dimethylmorpholin-4-yl)-5-fluoropyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1COC(C)(C)CN1C(C(=C1)F)=NC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 WPLSNJRTQSTZGY-UHFFFAOYSA-N 0.000 claims description 3
- TZDULZPTEMCBGU-UHFFFAOYSA-N 6-[[2-[[6-(2,2-dimethylmorpholin-4-yl)-5-fluoropyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1COC(C)(C)CN1C(C(=C1)F)=NC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 TZDULZPTEMCBGU-UHFFFAOYSA-N 0.000 claims description 3
- JPPONNNNUCFHBE-UHFFFAOYSA-N 6-[[2-[[6-(2,2-dimethylmorpholin-4-yl)-5-methylpyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CN=C1N1CCOC(C)(C)C1 JPPONNNNUCFHBE-UHFFFAOYSA-N 0.000 claims description 3
- JCAPQQOYKKTCHV-UHFFFAOYSA-N 6-[[2-[[6-(2,2-dimethylmorpholin-4-yl)-5-methylpyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)COC4=CC=3)C(F)=CN=2)=CN=C1N1CCOC(C)(C)C1 JCAPQQOYKKTCHV-UHFFFAOYSA-N 0.000 claims description 3
- AQIBZUFMVIUSCG-UHFFFAOYSA-N 6-[[2-[[6-(2,5-dimethylmorpholin-4-yl)pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1COC(C)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 AQIBZUFMVIUSCG-UHFFFAOYSA-N 0.000 claims description 3
- KLCGBJOXPZWFHE-UHFFFAOYSA-N 6-[[2-[[6-(4-ethoxypiperidin-1-yl)pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(OCC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 KLCGBJOXPZWFHE-UHFFFAOYSA-N 0.000 claims description 3
- PTJRUGNXIIIPLC-UHFFFAOYSA-N 6-[[2-[[6-(dimethylamino)pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1=NC(N(C)C)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 PTJRUGNXIIIPLC-UHFFFAOYSA-N 0.000 claims description 3
- VLKZSABFCITESO-OKILXGFUSA-N 6-[[2-[[6-[(2r,6s)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 VLKZSABFCITESO-OKILXGFUSA-N 0.000 claims description 3
- WZWGYXYCWPIQLX-OAHLLOKOSA-N 6-[[2-[[6-[(3r)-3-(ethylamino)pyrrolidin-1-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@H](NCC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 WZWGYXYCWPIQLX-OAHLLOKOSA-N 0.000 claims description 3
- YZEDMXPWRMYRRR-OAHLLOKOSA-N 6-[[2-[[6-[(3r)-3-ethoxypyrrolidin-1-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@H](OCC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 YZEDMXPWRMYRRR-OAHLLOKOSA-N 0.000 claims description 3
- GUVPOVFQVDZJSY-UHFFFAOYSA-N 6-[[2-[[6-[3-(diethylamino)pyrrolidin-1-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1C(N(CC)CC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 GUVPOVFQVDZJSY-UHFFFAOYSA-N 0.000 claims description 3
- NCCBQCQDVCGDDD-UHFFFAOYSA-N 6-[[2-[[6-[3-(ethoxymethyl)morpholin-4-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CCOCC1COCCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 NCCBQCQDVCGDDD-UHFFFAOYSA-N 0.000 claims description 3
- JDNSUONOYLDXHW-UHFFFAOYSA-N 6-[[2-[[6-[4-(diethylamino)piperidin-1-yl]pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(N(CC)CC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 JDNSUONOYLDXHW-UHFFFAOYSA-N 0.000 claims description 3
- KLKDQWKIEQIVMX-UHFFFAOYSA-N 6-[[5-fluoro-2-[(5-fluoro-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1F)=CN=C1N1CCOCC1 KLKDQWKIEQIVMX-UHFFFAOYSA-N 0.000 claims description 3
- JSEPZRMEBFKSNP-UHFFFAOYSA-N 6-[[5-fluoro-2-[(5-fluoro-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C(NC=2N=C3NC(=O)COC3=CC=2)C(F)=CN=C1NC(C=C1F)=CN=C1N1CCOCC1 JSEPZRMEBFKSNP-UHFFFAOYSA-N 0.000 claims description 3
- HQQFUXDKUMFWJU-UHFFFAOYSA-N 6-[[5-fluoro-2-[(5-methoxy-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CN=C1N1CCOCC1 HQQFUXDKUMFWJU-UHFFFAOYSA-N 0.000 claims description 3
- YGHLCQZDYAFXPK-UHFFFAOYSA-N 6-[[5-fluoro-2-[(5-methyl-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CN=C1N1CCOCC1 YGHLCQZDYAFXPK-UHFFFAOYSA-N 0.000 claims description 3
- UURMTYJYGUUZKV-UHFFFAOYSA-N 6-[[5-fluoro-2-[(5-methyl-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)COC4=CC=3)C(F)=CN=2)=CN=C1N1CCOCC1 UURMTYJYGUUZKV-UHFFFAOYSA-N 0.000 claims description 3
- IGLMOXQVWDIYHS-UHFFFAOYSA-N 6-[[5-fluoro-2-[(6-methylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1=NC(C)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 IGLMOXQVWDIYHS-UHFFFAOYSA-N 0.000 claims description 3
- WNIJAVTZKHTPCP-UHFFFAOYSA-N 6-[[5-fluoro-2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCOCC1 WNIJAVTZKHTPCP-UHFFFAOYSA-N 0.000 claims description 3
- GEIZBFSXAAHZAR-UHFFFAOYSA-N 6-[[5-fluoro-2-[(6-pyridin-3-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1C1=CC=CN=C1 GEIZBFSXAAHZAR-UHFFFAOYSA-N 0.000 claims description 3
- NPVRYCBJFSJIHV-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(1,4-oxazepan-4-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCCOCC1 NPVRYCBJFSJIHV-UHFFFAOYSA-N 0.000 claims description 3
- GFRNFHYHDKVXKS-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(2-oxo-1,3-oxazolidin-3-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCOC1=O GFRNFHYHDKVXKS-UHFFFAOYSA-N 0.000 claims description 3
- ZYCQBISJACHKPA-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(3-hydroxyazetidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CC(O)C1 ZYCQBISJACHKPA-UHFFFAOYSA-N 0.000 claims description 3
- XBWWMPFFBHDGTN-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(3-methylidenemorpholin-4-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCOCC1=C XBWWMPFFBHDGTN-UHFFFAOYSA-N 0.000 claims description 3
- SECGRXMXWOIZJZ-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(3-morpholin-4-ylpyrrolidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N(C1)CCC1N1CCOCC1 SECGRXMXWOIZJZ-UHFFFAOYSA-N 0.000 claims description 3
- ZVOZLRNNZQXGNZ-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(4-hydroxypiperidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCC(O)CC1 ZVOZLRNNZQXGNZ-UHFFFAOYSA-N 0.000 claims description 3
- OIYFGNOFQNMHKN-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(4-morpholin-4-ylpiperidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N(CC1)CCC1N1CCOCC1 OIYFGNOFQNMHKN-UHFFFAOYSA-N 0.000 claims description 3
- WIMBWLBGQZNTQQ-KBPBESRZSA-N 6-[[5-fluoro-2-[[6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1C(C)(C)C(=O)NC2=NC(NC=3C(F)=CN=C(N=3)NC3=CC=C(N=C3)N3C[C@]4(OC[C@]3([H])C4)[H])=CC=C21 WIMBWLBGQZNTQQ-KBPBESRZSA-N 0.000 claims description 3
- ZIWXRKMWNMTSAV-AWEZNQCLSA-N 6-[[5-fluoro-2-[[6-[(2r)-2-(fluoromethyl)morpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCO[C@@H](CF)C1 ZIWXRKMWNMTSAV-AWEZNQCLSA-N 0.000 claims description 3
- YVSXKHOYGWNIMK-GFCCVEGCSA-N 6-[[5-fluoro-2-[[6-[(2r)-2-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@H](C)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 YVSXKHOYGWNIMK-GFCCVEGCSA-N 0.000 claims description 3
- YVSXKHOYGWNIMK-LBPRGKRZSA-N 6-[[5-fluoro-2-[[6-[(2s)-2-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@@H](C)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 YVSXKHOYGWNIMK-LBPRGKRZSA-N 0.000 claims description 3
- VIBOBCDICAAZKZ-CYBMUJFWSA-N 6-[[5-fluoro-2-[[6-[(3r)-3-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C[C@@H]1COCCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 VIBOBCDICAAZKZ-CYBMUJFWSA-N 0.000 claims description 3
- HYOJTZDDHGDBMB-GFCCVEGCSA-N 6-[[5-fluoro-2-[[6-[(3r)-3-methylmorpholin-4-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C[C@@H]1COCCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 HYOJTZDDHGDBMB-GFCCVEGCSA-N 0.000 claims description 3
- BPXINNYJSNWKDA-ZDUSSCGKSA-N 6-[[5-fluoro-2-[[6-[(3s)-3-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CC[C@H](CO)C1 BPXINNYJSNWKDA-ZDUSSCGKSA-N 0.000 claims description 3
- NBQDFXCSTYIJDY-LBPRGKRZSA-N 6-[[5-fluoro-2-[[6-[(3s)-3-hydroxypyrrolidin-1-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@@H](O)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 NBQDFXCSTYIJDY-LBPRGKRZSA-N 0.000 claims description 3
- ZUIAFMJMJDQTAJ-HNNXBMFYSA-N 6-[[5-fluoro-2-[[6-[(4r)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC(C)[C@@H]1COC(=O)N1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 ZUIAFMJMJDQTAJ-HNNXBMFYSA-N 0.000 claims description 3
- BITZZFDTHYKJFF-KEKZHRQWSA-N 6-[[5-fluoro-2-[[6-[[(1r)-1-(oxolan-2-yl)ethyl]amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1([C@H](NC=2N=CC(NC=3N=C(NC=4N=C5NC(=O)COC5=CC=4)C(F)=CN=3)=CC=2)C)CCCO1 BITZZFDTHYKJFF-KEKZHRQWSA-N 0.000 claims description 3
- YSDHUYAFHVVOBE-KNVGNIICSA-N 6-[[5-fluoro-2-[[6-[[(1s)-1-(oxolan-2-yl)ethyl]amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1([C@@H](NC=2N=CC(NC=3N=C(NC=4N=C5NC(=O)C(C)(C)OC5=CC=4)C(F)=CN=3)=CC=2)C)CCCO1 YSDHUYAFHVVOBE-KNVGNIICSA-N 0.000 claims description 3
- BITZZFDTHYKJFF-SFVWDYPZSA-N 6-[[5-fluoro-2-[[6-[[(1s)-1-(oxolan-2-yl)ethyl]amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1([C@@H](NC=2N=CC(NC=3N=C(NC=4N=C5NC(=O)COC5=CC=4)C(F)=CN=3)=CC=2)C)CCCO1 BITZZFDTHYKJFF-SFVWDYPZSA-N 0.000 claims description 3
- PMMVYMCEKPKRMI-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-[methyl(oxan-4-yl)amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C=1C=C(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)C=NC=1N(C)C1CCOCC1 PMMVYMCEKPKRMI-UHFFFAOYSA-N 0.000 claims description 3
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- HVDLGVUKTPQIGT-UHFFFAOYSA-N 6-[[2-[[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridin-3-yl]amino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CCN2CCC1CC2 HVDLGVUKTPQIGT-UHFFFAOYSA-N 0.000 claims description 2
- KVAXNAOKWBLSNX-UHFFFAOYSA-N 6-[[5-fluoro-2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C(NC=2N=C3NC(=O)COC3=CC=2)C(F)=CN=C1NC(C=N1)=CC=C1N1CCOCC1 KVAXNAOKWBLSNX-UHFFFAOYSA-N 0.000 claims description 2
- XRFIOTODFLTNRN-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(2-oxa-8-azaspiro[4.5]decan-8-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N(CC1)CCC21CCOC2 XRFIOTODFLTNRN-UHFFFAOYSA-N 0.000 claims description 2
- ZBGZEUOWFKDVKC-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(3-methoxyazetidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1C(OC)CN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 ZBGZEUOWFKDVKC-UHFFFAOYSA-N 0.000 claims description 2
- WAPBSZLEEGPPLJ-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 WAPBSZLEEGPPLJ-UHFFFAOYSA-N 0.000 claims description 2
- JYRBPGWONFFDAY-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 JYRBPGWONFFDAY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical group NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 14
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- GYHAXELHINTZKS-UHFFFAOYSA-N 6-[[5-fluoro-2-[[6-(4-methoxypiperidin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(OC)CCN1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 GYHAXELHINTZKS-UHFFFAOYSA-N 0.000 claims 2
- ZUIAFMJMJDQTAJ-OAHLLOKOSA-N 6-[[5-fluoro-2-[[6-[(4s)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC(C)[C@H]1COC(=O)N1C(N=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 ZUIAFMJMJDQTAJ-OAHLLOKOSA-N 0.000 claims 2
- YSDHUYAFHVVOBE-JBZHPUCOSA-N 6-[[5-fluoro-2-[[6-[[(1r)-1-(oxolan-2-yl)ethyl]amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1([C@H](NC=2N=CC(NC=3N=C(NC=4N=C5NC(=O)C(C)(C)OC5=CC=4)C(F)=CN=3)=CC=2)C)CCCO1 YSDHUYAFHVVOBE-JBZHPUCOSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 125000005551 pyridylene group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241001420836 Ophthalmitis Species 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000010403 panophthalmitis Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 125000005549 heteroarylene group Chemical group 0.000 description 5
- KCWVVHMTNMXRBY-UHFFFAOYSA-N 6-[[5-fluoro-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCOCC1 KCWVVHMTNMXRBY-UHFFFAOYSA-N 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GIFJHZLZRZPIST-UHFFFAOYSA-N 6-[[5-fluoro-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C(NC=2N=C3NC(=O)COC3=CC=2)C(F)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 GIFJHZLZRZPIST-UHFFFAOYSA-N 0.000 description 3
- OQVWKULTWLTOAT-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 OQVWKULTWLTOAT-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- ANHQLUBMNSSPBV-UHFFFAOYSA-N 4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1=CN=C2NC(=O)COC2=C1 ANHQLUBMNSSPBV-UHFFFAOYSA-N 0.000 description 2
- HUSOKGLTYKFMAM-AWEZNQCLSA-N 6-[[5-fluoro-2-[4-[(3s)-3-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C[C@H]1COCCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 HUSOKGLTYKFMAM-AWEZNQCLSA-N 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- ZQHJAAMMKABEBS-UHFFFAOYSA-N morpholin-2-one Chemical compound O=C1CNCCO1 ZQHJAAMMKABEBS-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- FWOZENMJRAWVSD-UHFFFAOYSA-N spiro[4h-pyrido[3,2-b][1,4]oxazine-2,1'-cyclobutane]-3-one Chemical compound O=C1NC2=NC=CC=C2OC11CCC1 FWOZENMJRAWVSD-UHFFFAOYSA-N 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- QLBOHMYRHAJQGT-UHFFFAOYSA-N 1-[4-[[4-[(2,2-dimethyl-3-oxo-4h-pyrido[3,2-b][1,4]oxazin-6-yl)amino]-5-fluoropyrimidin-2-yl]amino]phenyl]piperidine-4-carbonitrile Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCC(C#N)CC1 QLBOHMYRHAJQGT-UHFFFAOYSA-N 0.000 description 1
- BVYMWZUXNJVZML-UHFFFAOYSA-N 1-[4-[[4-[(2,2-dimethyl-3-oxo-4h-pyrido[3,2-b][1,4]oxazin-6-yl)amino]-5-fluoropyrimidin-2-yl]amino]phenyl]piperidine-4-carboxamide Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCC(C(N)=O)CC1 BVYMWZUXNJVZML-UHFFFAOYSA-N 0.000 description 1
- QYGARPHDDICHDO-UHFFFAOYSA-N 6-[[2-(2,4,4a,5-tetrahydro-1h-[1,4]oxazino[3,4-c][1,4]benzoxazin-8-ylamino)-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1CC(=O)NC2=NC(NC3=NC(NC=4C=C5OCC6COCCN6C5=CC=4)=NC=C3F)=CC=C21 QYGARPHDDICHDO-UHFFFAOYSA-N 0.000 description 1
- ARAIZJCGTPAUIY-UHFFFAOYSA-N 6-[[2-(3,5-difluoro-4-morpholin-4-ylanilino)-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1F)=CC(F)=C1N1CCOCC1 ARAIZJCGTPAUIY-UHFFFAOYSA-N 0.000 description 1
- LXOSBSPZUBSSOI-UHFFFAOYSA-N 6-[[2-[3-(difluoromethoxy)-4-morpholin-4-ylanilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1OC(F)F)=CC=C1N1CCOCC1 LXOSBSPZUBSSOI-UHFFFAOYSA-N 0.000 description 1
- IRRGRXCCLNUWMT-UHFFFAOYSA-N 6-[[2-[4-(2,2-dimethylmorpholin-4-yl)anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1COC(C)(C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 IRRGRXCCLNUWMT-UHFFFAOYSA-N 0.000 description 1
- GURXUJOTOFVLIB-UHFFFAOYSA-N 6-[[2-[4-(2,2-dimethylmorpholin-4-yl)anilino]-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1COC(C)(C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 GURXUJOTOFVLIB-UHFFFAOYSA-N 0.000 description 1
- NDWCIWDDBHXUSR-UHFFFAOYSA-N 6-[[2-[4-(4,4-difluoropiperidin-1-yl)-3-fluoroanilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1F)=CC=C1N1CCC(F)(F)CC1 NDWCIWDDBHXUSR-UHFFFAOYSA-N 0.000 description 1
- XQBLWCWYVKEZRT-UHFFFAOYSA-N 6-[[2-[4-(4,4-difluoropiperidin-1-yl)anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCC(F)(F)CC1 XQBLWCWYVKEZRT-UHFFFAOYSA-N 0.000 description 1
- HTEHNNMBXLAURT-UHFFFAOYSA-N 6-[[2-[4-(4-aminopiperidin-1-yl)anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCC(N)CC1 HTEHNNMBXLAURT-UHFFFAOYSA-N 0.000 description 1
- QCIPVRLGKDDBTG-UHFFFAOYSA-N 6-[[2-[4-(4-ethoxypiperidin-1-yl)anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(OCC)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 QCIPVRLGKDDBTG-UHFFFAOYSA-N 0.000 description 1
- GIJZTBXEKBGSJX-GASCZTMLSA-N 6-[[2-[4-[(2r,6s)-2,6-dimethylmorpholin-4-yl]anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 GIJZTBXEKBGSJX-GASCZTMLSA-N 0.000 description 1
- BMWJAVANSAMNTN-OKILXGFUSA-N 6-[[2-[4-[(2r,6s)-2,6-dimethylmorpholin-4-yl]anilino]-5-fluoropyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 BMWJAVANSAMNTN-OKILXGFUSA-N 0.000 description 1
- IEDMYLDKMVJFHC-UHFFFAOYSA-N 6-[[2-[4-[4-(diethylamino)piperidin-1-yl]anilino]-5-fluoropyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(N(CC)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 IEDMYLDKMVJFHC-UHFFFAOYSA-N 0.000 description 1
- IOJKPXSZKXLGLN-UHFFFAOYSA-N 6-[[5-fluoro-2-(3-fluoro-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1F)=CC=C1N1CCOCC1 IOJKPXSZKXLGLN-UHFFFAOYSA-N 0.000 description 1
- QRZDAQOPASVHJK-UHFFFAOYSA-N 6-[[5-fluoro-2-(3-fluoro-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C(NC=2N=C3NC(=O)COC3=CC=2)C(F)=CN=C1NC(C=C1F)=CC=C1N1CCOCC1 QRZDAQOPASVHJK-UHFFFAOYSA-N 0.000 description 1
- UFOAIOLBHOCGFB-UHFFFAOYSA-N 6-[[5-fluoro-2-(3-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CC=C1N1CCOCC1 UFOAIOLBHOCGFB-UHFFFAOYSA-N 0.000 description 1
- JGPYHXSLRLWEID-UHFFFAOYSA-N 6-[[5-fluoro-2-(3-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=CC(NC=2N=C(NC=3N=C4NC(=O)COC4=CC=3)C(F)=CN=2)=CC=C1N1CCOCC1 JGPYHXSLRLWEID-UHFFFAOYSA-N 0.000 description 1
- RAZASVVIJLHCCM-UHFFFAOYSA-N 6-[[5-fluoro-2-(3-methyl-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CC=C1N1CCOCC1 RAZASVVIJLHCCM-UHFFFAOYSA-N 0.000 description 1
- STTRPMKIYAHHRO-UHFFFAOYSA-N 6-[[5-fluoro-2-(4-morpholin-4-yl-3-propan-2-yloxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC(C)OC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CC=C1N1CCOCC1 STTRPMKIYAHHRO-UHFFFAOYSA-N 0.000 description 1
- ZZJLCJZQXLUVMB-UHFFFAOYSA-N 6-[[5-fluoro-2-(4-piperidin-1-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCCCC1 ZZJLCJZQXLUVMB-UHFFFAOYSA-N 0.000 description 1
- AXKXDYSEJYWLJX-UHFFFAOYSA-N 6-[[5-fluoro-2-(4-thiomorpholin-4-ylanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCSCC1 AXKXDYSEJYWLJX-UHFFFAOYSA-N 0.000 description 1
- AHEMIYKAXHYEPT-UHFFFAOYSA-N 6-[[5-fluoro-2-(isoquinolin-7-ylamino)pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1=CN=CC2=CC(NC=3N=C(C(=CN=3)F)NC3=CC=C4OC(C(NC4=N3)=O)(C)C)=CC=C21 AHEMIYKAXHYEPT-UHFFFAOYSA-N 0.000 description 1
- JZZFMAMDBUTHJO-UHFFFAOYSA-N 6-[[5-fluoro-2-[(2-pyridin-4-yl-3h-benzimidazol-5-yl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1N2)=CC=C1N=C2C1=CC=NC=C1 JZZFMAMDBUTHJO-UHFFFAOYSA-N 0.000 description 1
- RSXZKIATPPSZMT-AWEZNQCLSA-N 6-[[5-fluoro-2-[2-[(2s)-2-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@@H](C)CN1C1=CC=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 RSXZKIATPPSZMT-AWEZNQCLSA-N 0.000 description 1
- BEZFQCDMZLJQFG-ZDUSSCGKSA-N 6-[[5-fluoro-2-[2-[(2s)-2-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@@H](C)CN1C1=CC=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 BEZFQCDMZLJQFG-ZDUSSCGKSA-N 0.000 description 1
- HPUMJUDSCPRDRH-UHFFFAOYSA-N 6-[[5-fluoro-2-[3-fluoro-4-[3-(hydroxymethyl)morpholin-4-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1F)=CC=C1N1CCOCC1CO HPUMJUDSCPRDRH-UHFFFAOYSA-N 0.000 description 1
- YPWMMHUGNMZGRX-UHFFFAOYSA-N 6-[[5-fluoro-2-[3-methyl-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound CC1=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=CC=C1N(CC1)CCC21CCOC2 YPWMMHUGNMZGRX-UHFFFAOYSA-N 0.000 description 1
- WRXCJUXXNQGICC-HOTGVXAUSA-N 6-[[5-fluoro-2-[3-methyl-4-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1C(C)(C)C(=O)NC2=NC(NC=3C(F)=CN=C(N=3)NC3=CC=C(C(=C3)C)N3C[C@]4(OC[C@]3([H])C4)[H])=CC=C21 WRXCJUXXNQGICC-HOTGVXAUSA-N 0.000 description 1
- FJHOXTMXCWXMIB-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(1,4-oxazepan-4-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCCOCC1 FJHOXTMXCWXMIB-UHFFFAOYSA-N 0.000 description 1
- MISQSWJMAGJWGC-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(1-oxa-8-azaspiro[4.5]decan-8-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N(CC1)CCC21CCCO2 MISQSWJMAGJWGC-UHFFFAOYSA-N 0.000 description 1
- IKUOYGJLTIRCMP-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N(CC1)CCC21COC2 IKUOYGJLTIRCMP-UHFFFAOYSA-N 0.000 description 1
- FGMVSQWEFPCOLB-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(2-oxa-8-azaspiro[4.5]decan-8-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N(CC1)CCC21CCOC2 FGMVSQWEFPCOLB-UHFFFAOYSA-N 0.000 description 1
- FUGQXRHJCOWWQL-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(2-oxo-1,3-oxazolidin-3-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCOC1=O FUGQXRHJCOWWQL-UHFFFAOYSA-N 0.000 description 1
- ZCLFYNCZIINNEW-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(3-oxopiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCNC(=O)C1 ZCLFYNCZIINNEW-UHFFFAOYSA-N 0.000 description 1
- ISUCCCZPNWLSOV-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(4-hydroxypiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCC(O)CC1 ISUCCCZPNWLSOV-UHFFFAOYSA-N 0.000 description 1
- FFKFKFJREYLHPK-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(4-methoxypiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(OC)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 FFKFKFJREYLHPK-UHFFFAOYSA-N 0.000 description 1
- JMEORTQATRPODA-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(4-morpholin-4-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N(CC1)CCC1N1CCOCC1 JMEORTQATRPODA-UHFFFAOYSA-N 0.000 description 1
- ZCSSAZIPEOVHEE-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-(4-propan-2-yloxypiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(OC(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 ZCSSAZIPEOVHEE-UHFFFAOYSA-N 0.000 description 1
- AUESMCKAJYFIQY-HOTGVXAUSA-N 6-[[5-fluoro-2-[4-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1C(C)(C)C(=O)NC2=NC(NC=3C(F)=CN=C(N=3)NC3=CC=C(C=C3)N3C[C@]4(OC[C@]3([H])C4)[H])=CC=C21 AUESMCKAJYFIQY-HOTGVXAUSA-N 0.000 description 1
- HOMYVFHPVPSQLI-GJZGRUSLSA-N 6-[[5-fluoro-2-[4-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]anilino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1CC(=O)NC2=NC(NC=3C(F)=CN=C(N=3)NC3=CC=C(C=C3)N3C[C@]4(OC[C@]3([H])C4)[H])=CC=C21 HOMYVFHPVPSQLI-GJZGRUSLSA-N 0.000 description 1
- KNSDZFCWEMZEOS-CQSZACIVSA-N 6-[[5-fluoro-2-[4-[(2r)-2-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 KNSDZFCWEMZEOS-CQSZACIVSA-N 0.000 description 1
- JEVCQEQZKKONPG-CYBMUJFWSA-N 6-[[5-fluoro-2-[4-[(2r)-2-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CO[C@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 JEVCQEQZKKONPG-CYBMUJFWSA-N 0.000 description 1
- XHJGMELRULAGJB-ZDUSSCGKSA-N 6-[[5-fluoro-2-[4-[(3s)-3-methylmorpholin-4-yl]anilino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C[C@H]1COCCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 XHJGMELRULAGJB-ZDUSSCGKSA-N 0.000 description 1
- PWZQITAXMNZNDO-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-[2-(2-hydroxyethyl)morpholin-4-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1N1CCOC(CCO)C1 PWZQITAXMNZNDO-UHFFFAOYSA-N 0.000 description 1
- YOCIXYLGWNZLNA-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-[2-(2-hydroxyethyl)morpholin-4-yl]anilino]pyrimidin-4-yl]amino]-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1COC(CCO)CN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 YOCIXYLGWNZLNA-UHFFFAOYSA-N 0.000 description 1
- MEYGUGZSFYCLJW-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-[4-(methoxymethyl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1CC(COC)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)C(C)(C)OC3=CC=2)=N1 MEYGUGZSFYCLJW-UHFFFAOYSA-N 0.000 description 1
- SRIODVYLIANSKY-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-morpholin-4-yl-3-(trifluoromethoxy)anilino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1OC(F)(F)F)=CC=C1N1CCOCC1 SRIODVYLIANSKY-UHFFFAOYSA-N 0.000 description 1
- ZUCHFUDTIXYYQR-UHFFFAOYSA-N 6-[[5-fluoro-2-[4-morpholin-4-yl-3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]-4-propylpyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2N(CCC)C(=O)COC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=C1C(F)(F)F)=CC=C1N1CCOCC1 ZUCHFUDTIXYYQR-UHFFFAOYSA-N 0.000 description 1
- CRKJVHHSFFBHGY-UHFFFAOYSA-N 6-[[5-fluoro-2-[[4-[(4-hydroxycyclohexyl)amino]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC1=CN=CC=C1NC1CCC(O)CC1 CRKJVHHSFFBHGY-UHFFFAOYSA-N 0.000 description 1
- NVFWLMVCNGLSGK-GFCCVEGCSA-N 6-[[5-fluoro-2-[[6-[(3r)-3-fluoropyrrolidin-1-yl]pyridin-3-yl]amino]pyrimidin-4-yl]amino]-2,2-dimethyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1=C2NC(=O)C(C)(C)OC2=CC=C1NC(C(=CN=1)F)=NC=1NC(C=N1)=CC=C1N1CC[C@@H](F)C1 NVFWLMVCNGLSGK-GFCCVEGCSA-N 0.000 description 1
- WUCMAILKZOYRQL-UHFFFAOYSA-N CC(C)(C(N1)=O)OC(C=C2)=C1N=C2C(N=C(NC1=CC=C(N(CC2)CCC2OC)N=C1)N=C1N)=C1F Chemical compound CC(C)(C(N1)=O)OC(C=C2)=C1N=C2C(N=C(NC1=CC=C(N(CC2)CCC2OC)N=C1)N=C1N)=C1F WUCMAILKZOYRQL-UHFFFAOYSA-N 0.000 description 1
- PFGOKHCHOPRQSB-KEKZHRQWSA-N C[C@H](C1OCCC1)NC(N=C1)=CC=C1NC(N=C1N)=NC(C(C=C2)=NC(N3)=C2OC(C)(C)C3=O)=C1F Chemical compound C[C@H](C1OCCC1)NC(N=C1)=CC=C1NC(N=C1N)=NC(C(C=C2)=NC(N3)=C2OC(C)(C)C3=O)=C1F PFGOKHCHOPRQSB-KEKZHRQWSA-N 0.000 description 1
- SPBIMIYCSQFUFJ-UHFFFAOYSA-N NC1=NC(NC(C=C2)=CC=C2N2CCOCCC2)=NC(C(C=C2)=NC(N3)=C2OCC3=O)=C1F Chemical compound NC1=NC(NC(C=C2)=CC=C2N2CCOCCC2)=NC(C(C=C2)=NC(N3)=C2OCC3=O)=C1F SPBIMIYCSQFUFJ-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- ZEHKEBFEQQGQHQ-UHFFFAOYSA-N ethyl 4-[2-[[5-fluoro-4-[(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-6-yl)amino]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=CC=C1NC1=NC=C(F)C(NC=2N=C3NC(=O)COC3=CC=2)=N1 ZEHKEBFEQQGQHQ-UHFFFAOYSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32369910P | 2010-04-13 | 2010-04-13 | |
| US61/323,699 | 2010-04-13 | ||
| PCT/US2011/032291 WO2011130390A1 (en) | 2010-04-13 | 2011-04-13 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015193022A Division JP2016041700A (ja) | 2010-04-13 | 2015-09-30 | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523891A JP2013523891A (ja) | 2013-06-17 |
| JP2013523891A5 true JP2013523891A5 (enExample) | 2014-05-29 |
| JP6067550B2 JP6067550B2 (ja) | 2017-01-25 |
Family
ID=44583348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505087A Active JP6067550B2 (ja) | 2010-04-13 | 2011-04-13 | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
| JP2015193022A Pending JP2016041700A (ja) | 2010-04-13 | 2015-09-30 | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015193022A Pending JP2016041700A (ja) | 2010-04-13 | 2015-09-30 | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8618095B2 (enExample) |
| EP (1) | EP2558474B1 (enExample) |
| JP (2) | JP6067550B2 (enExample) |
| CA (1) | CA2792278C (enExample) |
| ES (1) | ES2562419T3 (enExample) |
| WO (1) | WO2011130390A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130390A1 (en) * | 2010-04-13 | 2011-10-20 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013014454A1 (en) | 2011-07-28 | 2013-01-31 | Astrazeneca Ab | New (trimethoxyphenylamino)pyrimidinyl formulations |
| US9676870B2 (en) * | 2011-08-04 | 2017-06-13 | The Brigham And Women's Hospital, Inc. | Methods of treating atherosclerosis and aneurysm |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| CN103958526B (zh) * | 2012-06-20 | 2015-09-09 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| CN102746337B (zh) * | 2012-06-21 | 2014-12-17 | 成都苑东药业有限公司 | 一种2，4-嘧啶二胺类化合物及其制备方法 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2890698B1 (en) * | 2012-08-30 | 2017-03-01 | F. Hoffmann-La Roche AG | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014138979A1 (en) | 2013-03-13 | 2014-09-18 | Canadian Blood Services | Pyrazole derivatives and their uses thereof |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP7118642B2 (ja) * | 2014-08-08 | 2022-08-16 | アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ | 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN116670127A (zh) * | 2021-03-30 | 2023-08-29 | 贝达药业股份有限公司 | Egfr抑制剂及其组合物和用途 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022236255A2 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4653444A1 (en) * | 2023-01-19 | 2025-11-26 | Hangzhou Innogate Pharma Co., Ltd. | Fused tricyclic compound as kinase inhibitor |
| CN119431398A (zh) * | 2023-07-31 | 2025-02-14 | 中国科学院上海有机化学研究所 | R406及其衍生物协同trail的抗肿瘤应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| FR2785284B1 (fr) | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
| US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
| US6924400B2 (en) | 2001-12-10 | 2005-08-02 | Galderma Research & Development, Snc | Triaromatic vitamin D analogues |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| RS51752B (sr) | 2002-07-29 | 2011-12-31 | Rigel Pharmaceuticals | Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina |
| EP1635773A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. (a New Jersey corp.) | Combination therapy for the treatment of hypertension |
| HRP20130602T1 (en) | 2003-07-30 | 2013-07-31 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| ES2365223T3 (es) | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
| US20070092888A1 (en) | 2003-09-23 | 2007-04-26 | Cornelius Diamond | Diagnostic markers of hypertension and methods of use thereof |
| DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| US8163902B2 (en) | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2008118823A2 (en) | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2542884T3 (es) | 2008-09-23 | 2015-08-12 | Rigel Pharmaceuticals, Inc. | Inhibidores de JAK de carbamato tricíclico |
| ES2624622T3 (es) | 2008-12-30 | 2017-07-17 | Rigel Pharmaceuticals, Inc. | Inhibidores de pirimidindiamina cinasa |
| WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| WO2011130390A1 (en) * | 2010-04-13 | 2011-10-20 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
-
2011
- 2011-04-13 WO PCT/US2011/032291 patent/WO2011130390A1/en not_active Ceased
- 2011-04-13 JP JP2013505087A patent/JP6067550B2/ja active Active
- 2011-04-13 CA CA2792278A patent/CA2792278C/en active Active
- 2011-04-13 ES ES11730116.8T patent/ES2562419T3/es active Active
- 2011-04-13 US US13/086,081 patent/US8618095B2/en active Active
- 2011-04-13 EP EP11730116.8A patent/EP2558474B1/en active Active
-
2015
- 2015-09-30 JP JP2015193022A patent/JP2016041700A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523891A5 (enExample) | ||
| JP7641917B2 (ja) | Ｐ２ｘ３阻害剤としてのアミノキナゾリン誘導体 | |
| AU2017226004B2 (en) | Inhibitors of WDR5 protein-protein binding | |
| ES2823049T3 (es) | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| ES2823477T3 (es) | Aril éteres y usos de los mismos | |
| US9809610B2 (en) | Compounds and compositions as kinase inhibitors | |
| JP2024520791A (ja) | 化合物 | |
| ES2727376T3 (es) | Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK | |
| EP4277901A1 (en) | Isoindolinone compounds | |
| ES2580406T3 (es) | Radioligandos marcados con fluor-18 y carbono-11 para formación de imágenes por tomografía de emisión de positrones (PET) para LRRK2 | |
| SI2797918T1 (en) | Bromodomain inhibitors | |
| ES2688396T3 (es) | Compuestos de 1,3,4,tiadiazol y su uso en el tratamiento del cáncer | |
| WO2016024185A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| ES2635003T3 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET | |
| CN116323623A (zh) | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 | |
| AU2018209667A1 (en) | JAK1 selective inhibitors | |
| WO2016034673A1 (en) | Tetrahydroisoquinoline derived prmt5-inhibitors | |
| CN107074828A (zh) | 用作raf激酶抑制剂的化合物和组合物 | |
| CN111527090B (zh) | 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物 | |
| EP3189048A1 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors | |
| CA3005517C (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| JP7763753B2 (ja) | アザキノリン化合物およびその使用 | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |